arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Black Diamond Therapeutics, Inc.

BDTX

$1.96 ▲ +0.05 (+2.62%) at close

9 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Black Diamond Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $111.5M

Dividend Yield —

Revenue Growth —

Op. Margin 17.9%

ROIC 8.8% ↗

FCF / Share $0.52 ↗

Trailing P/E 5.0x

Price / Book 1.0x

FCF Yield 26.6%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$70.00M

— —

Net Income Profit after all expenses

$22.37M

↑ +132.1% —

FCF / Share Free cash flow per share

$0.52

↑ +146.0% —

trending_up

Bullish Indicators

Profit Margin (%)Profit Margin (%) is in the top quartile
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	N/M	32.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	25.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	27.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-69.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	N/M	15.5% Good ↑ Good Improving Year-over-year change in net income	9.6% Fair ↑ Fair Improving Year-over-year change in net income	27.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-86.7% Weak ↑ Weak Improving Year-over-year change in net income	-90.7% Weak Weak Year-over-year change in net income	-294.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	25.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	35.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	17.4% Good Good Year-over-year change in free cash flow	-78.9% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	17.9% Fair Fair Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+19%)	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	32.0% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+166%)	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	42.3% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—
FCF / Net Income (x)	1.32x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	8.8% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	-74.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-58.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-51.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	49.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	45.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	8.8% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	-64.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-17.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	19.9% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+33%)	-83.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-658%)	-70.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-571%)	-78.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-625%)	-64.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-527%)	-21.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-246%)	74.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+398%)	57.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+283%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-69570.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-20.99M	$-36.44M	$-56.22M	$-34.31M	$-65.80M	$-34.60M	$-154.67M	$-51.66M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$1.23	$0.00	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$0.39	$-1.27	$-1.88	$-2.52	$-3.47	$-2.05	—	—	—
Free Cash Flow per Share (USD)	$0.52	$-1.13	$-1.52	$-2.35	$-2.84	$-1.59	—	—	—
Book Value per Share (USD)	$1.96	$1.47	$2.26	$3.18	$5.41	$8.53	$-21.08	$-7.15	—
Tangible Book Value per Share (USD)	$1.96	$1.47	$2.26	$3.18	$5.41	$8.53	$-21.08	$-7.15	—
Basic Weighted Avg Shares (shares)	56.87M	55.03M	43.95M	36.33M	36.19M	32.91M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$116.71M	$80.60M	$114.39M	$112.44M	$192.06M	$305.34M	$150.85M	$49.11M	—
Total Equity (USD)	$112.21M	$83.28M	$116.74M	$115.69M	$195.90M	$307.76M	$-47.16M	$-15.54M	$-6.67M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$70.00M	$0.00	—	—	—	—	$0.00	$0.00	—
Depreciation Expense (USD)	$325.00K	$343.00K	$437.00K	$508.00K	$205.00K	$52.00K	$47.00K	$44.00K	—
Net Income, GAAP (USD)	$22.37M	$-69.68M	$-82.44M	$-91.17M	$-125.60M	$-67.25M	$-35.26M	$-8.93M	—
Operating Cash Flow (USD)	$29.61M	$-62.30M	$-66.72M	$-85.08M	$-100.15M	$-52.15M	$-24.67M	$-8.45M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters

Black Diamond Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BDTX with peers